- ￥1248 - 2040
- AntibodySystem
- France
- RHD36993
- 2025年07月12日
- ELISA, FCM, WB
- Mouse
- Human
企业认证
相关产品推荐更多 >
Anti-GCN4 tag (HLENEVARLKK) Antibody (C11L34)（单克隆抗体，标签抗体）
￥960Anti-Strep Tag (WSHPQFEK) Monoclonal Antibody (1A188)（单克隆抗体，标签抗体）
￥780Anti-HA Tag (YPYDVPDYA) Antibody (12CA5)（单克隆抗体，标签抗体）
￥780Anti-PA tag (EGGVAMPGAEDDVV) Antibody (NZ-1)（单克隆抗体，标签抗体）
￥960Anti-GST-tag Monoclonal Antibody (1A214), HRP（单克隆抗体，标签抗体）
￥1170
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型：
VHH-mFc
- 形态：
Liquid
- 保存条件：
-20°C
- 克隆性：
单克隆
- 适应物种：
Human
- 供应商：
武汉益普生物科技有限公司
- 宿主：
Mouse
- 应用范围：
ELISA, FCM, WB
- 抗体英文名：
Anti-Human IgG Kappa Chain Antibody (SAA0278), FITC
- 规格：
50μg/100μg
| 规格： | 50μg | 产品价格： | ￥1248.0 |
|---|---|---|---|
| 规格： | 100μg | 产品价格： | ￥2040.0 |
| 产品名 | Anti-Human IgG Kappa Chain Antibody (SAA0278), FITC |
| 货号 | RHD36993 |
| 靶标 | Immunoglobulin kappa constant, Ig kappa chain C region, Ig kappa chain C region AG, Ig kappa chain C region CUM, Ig kappa chain C region EU, Ig kappa chain C region OU, Ig kappa chain C region ROY, Ig kappa chain C region TI, IGKC, second antibody, FITC, Fluorescein |
| 克隆号 | SAA0278 |
| 克隆类型 | Monoclonal |
| 同种型 | VHH-mFc |
| 宿主 | Mouse |
| 种属反应性 | Human |
| 应用 | ELISA, FCM, WB |
| 纯度 | >95% as determined by SDS-PAGE. |
| 内毒素水平 | Please contact with the lab for this information. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4, 0.2% BSA, 50% Glycerol, 0.05% Proclin 300. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 说明 | For research use only. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验4-Hydroxy-2-Nonenal (4-HNE) Staining by Anti-HNE Antibody
using an anti-4-HNE monoclonal antibody (MAb) (6 –8 ) and labeled goat anti-mouse IgG antibody (9 ).
Production of Chimeric Heavy-Chain Antibodies
Antibody has become a major category of therapeutics. However, IgG, the primary molecular format of existing antibody drugs, has some major shortcomings such as undesirable pharmacokinetics, high dose requirement, and high production cost
Notes on Making Rat x Y3 Monoclonal Antibody Producing Hybridomas
to the kappa 1a of Y3 (eg. DA which is kappa 1b) to allow later screening of myeloma light chain loss variants (if required). b) The final boost should be by the intravenous route, four days before the fusion, to ensure maximal activity in the spleen.
技术资料暂无技术资料 索取技术资料
